Drug Combination Details
| General Information of the Combination (ID: C01496) | |||||
|---|---|---|---|---|---|
| Name | Parthenolide NP Info | + | Balsalazide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Sixty specific pathogen-free mice (Balb/C female mice, 6 week) were used in this study. | |||||
| Experimental
Result(s) |
Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-KappaB Activation. Mol Cancer Res. 2017 Feb;15(2):141-151. | |||
